Chemical Property of Alemtuzumab
Chemical Property:
- Purity/Quality:
-
97% *data from raw suppliers
Alemtuzumab *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
-
Description
Alemtuzumab was first introduced in the US for the treatment of B-cell chronic
lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and
have failed fludarabine therapy. Alemtuzumab is a humanized monoclonal antibody of the
IgG1 isotype specific for the glycoprotein CD52 expressed on the cell surface of over 95%
of normal and malignant B and T lymphocytes and monocytes. It was genetically
engineered by adding six hypervariable regions from the heavy-chain and light-chain
variable domains of an IgG2a rat monoclonal antibody onto a human IgG1 immunoglobulin
molecule. The exact mechanism of action of alemtuzumab is unknown but the antibody
probably causes the lysis of lymphocytes via complement fixation and antibody-dependent
cytotoxicity. In a phase III clinical trial with 93 fiudarabine-resistant CLL patients, treatment
with alemtuzumab gave a positive response in 31 patients with 2 complete remissions and
29 partial remissions. This study demonstrated a higher response rate in patients having
malignancy confined to the blood and bone marrow. Alemtuzumab does not seem to
penetrate well into solid tissues and it was found to be concentrated in the blood which
seems to correlate with the fact that it appears to be inefficient against tumor cells from
lymph nodes and extranodal masses. The half-life of the antibody ranged between 23 and
30 hours. Premedication with acetaminophen and diphenhydramine is effective in reducing
infusion-related reactions such as fevers, rigors, rash, nausea or hypotension. The most
significant adverse effect is lymphopenia resulting in increased risk of opportunistic
infections. As a consequence, prophylactic treatment with antibiotics is recommended for
patients under alemtuzumab therapy.
-
Uses
Antineoplastic (monoclonal antibody).
-
Clinical Use
Treatment of chronic lymphocytic leukaemia (CLL)
not totally responsive to other treatment
Induction therapy in renal transplantation
Treatment of relapsing remitting multiple sclerosis
(MS)
-
Drug interactions
Potentially hazardous interactions with other drugs
Other chemotherapy: do not give within 3 weeks of
each other.
Live vaccines: avoid for at least 12 months after
treatment.
